Home / Stocks / RCDTF

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF, Drugmakers) Stock Valuation & Fair Value

Mixed on our tests

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF, Drugmakers) trades at a current P/E of 16.7, about 7% below its historical normal valuation, with a forward growth estimate of 13.3% and a PEG of 1.25. Analysts' one-year estimates have been hit 64% of the time. Priced at its historical normal P/E of 17.9 on the same blended earnings, the 2026-11-06 close of $59.32 corresponds to about $63.80 a share. This is a valuation reference, not a price target. The $59.32 close is the one the P/E is read at; the technical context below uses the 2026-11-05 close, $58.79.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
16.7
Normal P/E
17.9
PEG
1.25
Fwd growth
13.3%
Div yield
2.6%
RSI (14)
100.0
Overbought
Technical context
  • Price $58.79 at the Nov 5 close, level with the 20-day average ($58.79) and 0.7% above the 50-day ($58.41).
  • RSI (14) at 100.0.
  • 52-week range $55.17 to $64.61: the price is 9.0% below the high and 6.6% above the low.

Valuation flags

Verdict history

tickerseer's rating changed 4 times after 2026-09-19 and is back where it started: favorable on our tests as of 2026-11-02.

Current P/E and rating by weekCurrent P/E moved from 16.6 to 16.5 between 2026-09-18 and 2026-10-30, against a normal P/E of 17.9, with 4 rating changes over 7 recorded weeks.2026-09-18: P/E 16.6, Favorable on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 16.6, Favorable on our tests, recorded live 2026-09-212026-09-25: P/E 16.7, Mixed on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 16.7, Mixed on our tests, recorded live 2026-09-282026-10-02: P/E 16.4, Favorable on our tests, recalculated for the week of 2026-10-032026-10-02: P/E 16.4, Favorable on our tests, recorded live 2026-10-052026-10-09: P/E 16.5, Favorable on our tests, recalculated for the week of 2026-10-102026-10-09: P/E 16.5, Favorable on our tests, recorded live 2026-10-122026-10-16: P/E 16.6, Favorable on our tests, recalculated for the week of 2026-10-172026-10-16: P/E 16.6, Favorable on our tests, recorded live 2026-10-192026-10-23: P/E 16.9, Mixed on our tests, recalculated for the week of 2026-10-242026-10-23: P/E 16.9, Mixed on our tests, recorded live 2026-10-262026-10-30: P/E 16.5, Favorable on our tests, recalculated for the week of 2026-10-312026-10-30: P/E 16.5, Favorable on our tests, recorded live 2026-11-0216.517.017.5Sep 18Sep 28Oct 9Oct 20Oct 30Normal P/E 17.9
Favorable on our testsMixed on our tests

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 16.6-7%Favorable on our tests (recalculated)
2026-09-26P/E 16.7-7%Mixed on our tests (recalculated)
2026-10-03P/E 16.4-9%Favorable on our tests (recalculated)
2026-10-24P/E 16.9-6%Mixed on our tests (recalculated)
2026-10-31P/E 16.5-8%Favorable on our tests (recalculated) (across a rating rules change)
2026-11-02P/E 16.5-8%Favorable on our tests ← now
Show all 14 readings
WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 16.6-7%Favorable on our tests (recalculated)
2026-09-21P/E 16.6-7%Favorable on our tests
2026-09-26P/E 16.7-7%Mixed on our tests (recalculated)
2026-09-28P/E 16.7-7%Mixed on our tests
2026-10-03P/E 16.4-9%Favorable on our tests (recalculated)
2026-10-05P/E 16.4-9%Favorable on our tests
2026-10-10P/E 16.5-8%Favorable on our tests (recalculated)
2026-10-12P/E 16.5-8%Favorable on our tests
2026-10-17P/E 16.6-7%Favorable on our tests (recalculated)
2026-10-19P/E 16.6-7%Favorable on our tests
2026-10-24P/E 16.9-6%Mixed on our tests (recalculated)
2026-10-26P/E 16.9-6%Mixed on our tests
2026-10-31P/E 16.5-8%Favorable on our tests (recalculated) (across a rating rules change)
2026-11-02P/E 16.5-8%Favorable on our tests ← now

Frequently asked questions

Is Recordati Industria Chimica e Farmaceutica S.p.A. stock overvalued?

At a current P/E of 16.7 versus its historical normal P/E of 17.9, Recordati Industria Chimica e Farmaceutica S.p.A. trades about 7% below its typical valuation, with a PEG of 1.25 on 13.3% forward growth. tickerseer currently rates it mixed on our tests.

What is Recordati Industria Chimica e Farmaceutica S.p.A.'s fair value and PEG?

Recordati Industria Chimica e Farmaceutica S.p.A. trades at a current P/E of 16.7 against a historical normal P/E of 17.9, a PEG of 1.25, and a forward growth estimate of 13.3%. Priced at its historical normal P/E of 17.9 on the same blended earnings, the 2026-11-06 close of $59.32 corresponds to about $63.80 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Recordati Industria Chimica e Farmaceutica S.p.A. changed?

tickerseer's rating changed 4 times after 2026-09-19 and is back where it started: favorable on our tests as of 2026-11-02.

Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track RCDTF free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.